Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

NCT05933395 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

135

Enrollment

OTHER

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: Fulvestrant
DRUG: Neratinib
DRUG: Alpelisib
DRUG: Everolimus
DRUG: Abemaciclib

Sponsor

Dartmouth-Hitchcock Medical Center